Skip to content
Log in

Author

Huansheng Xu

View on Semantic Scholar

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#gene editing Aug 2026

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.

In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.

Luke J. Laffin, S. Nicholls, Russell S Scott et al. · 0 citations